Needham Maintains TransMedics(TMDX.US) With Hold Rating
TransMedics Group Analyst Ratings
TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $120
TransMedics Group: Strong Buy Rating Amidst Robust DCD Market Performance and Growth Prospects
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $90
Piper Sandler Remains a Buy on TransMedics Group (TMDX)
Needham Maintains TransMedics(TMDX.US) With Hold Rating
CCORF Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $104
TransMedics Group Price Target Maintained With a $104.00/Share by Canaccord Genuity
TransMedics Group Is Maintained at Buy by Canaccord Genuity
TransMedics Group Analyst Ratings
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $90
Piper Sandler Sticks to Its Buy Rating for TransMedics Group (TMDX)
Morgan Stanley Maintains TransMedics(TMDX.US) With Hold Rating, Maintains Target Price $80
A Quick Look at Today's Ratings for TransMedics(TMDX.US), With a Forecast Between $81 to $104
A Quick Look at Today's Ratings for TransMedics(TMDX.US), With a Forecast Between $90 to $120
Needham Remains a Hold on TransMedics Group (TMDX)
TransMedics Group's Strong Q4 Performance and Positive Outlook Justify Buy Rating
Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX) and Cardiff Oncology (CRDF)
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $90